Project Description
2N Pharma
2N Pharma are an international team of researchers, business people and partners who share the vision that patients with brain diseases must have at least as many applicable treatment options as, for examples, cancer patients have today.
Their drug candidate, Mitometin, is an orally administered, small molecule reversible inhibitor of carnitine palmitoyl transferase 1 (CPT1), a key enzyme in beta-oxidation as it facilitates transport of fatty acids across the mitochondrial membrane.
2N Pharma joined NOME in 2023 and was the winner of the 2023 Startup Competition.
